404 results on '"Stasi, R."'
Search Results
2. Profound sustained reticulocytopenia and anaemia in an adult patient with sickle cell disease
3. La porpora trombocitopenica idiopatica: una stima del costo della malattia in Italia
4. Gemtuzumab ozogamicin (Mylotarg®) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups
5. A new mathematical model based on clinical and laboratory variables for the diagnosis of Sjögren's syndrome
6. Measurement of macrophage marker in hyperhaemolytic transfusion reaction: a case report
7. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes
8. Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis
9. Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia
10. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab
11. Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing
12. A nearly Zero Energy Building in Mediterranean climate: a case study in Mesagne (Apulia)
13. Serum levels of tumour necrosis factor-α predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome
14. Efficacy and safety of human leucocyte interferon-α treatment in patients younger than 60 years of age with polycythaemia vera
15. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)
16. All-trans retinoic acid plus low doses of cytarabine for the treatment of “poor-risk” acute myeloid leukemias
17. Structural investigation of the VEGF receptor interaction with a helical antagonist peptide
18. High interleukin-6 plasma levels in acute promyelocytic leukemia
19. β-Hairpin peptide that targets vascular endothelial growth factor (VEGF) receptors: Design, NMR characterization, and biological activity
20. A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner
21. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia
22. Analysis of the haptoglobin binding region on the apolipoprotein A-I-derived P2a peptide
23. beta-Hairpin Peptide That Targets Vascular Endothelial Growth Factor (VEGF) Receptors: DESIGN, NMR CHARACTERIZATION, AND BIOLOGICAL ACTIVITY
24. Helical peptide as VEGF antagonist
25. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction mono- therapy for newly diagnosed acute myeloid leukaemia in older patients not considered candi- dates for intensive chemotherapy. A phase II study on the EORTC and GIMEMA leukaemia groups (AML-19)
26. NMR analysis of the interaction between VEGF mimicking peptides and VEGFR1D2
27. Design and biological characterization of a proangiogenic peptide reproducing the b-hairpin region 87-100 of PlGF
28. NMR strcutural characterization of a bioactive b-hairpin peptide and its interaction with VEGFR1D2
29. Expression of extracellular domains of VEGf receptors and their use in NMR drug discovery studies
30. Vascular Endothelial growth factor and its receptors: key regulators of angiogenesis
31. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab
32. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
33. Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17).
34. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes
35. AML-M0: A review of laboratory features and proposal of new diagnostic criteria
36. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19).
37. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
38. Red blood cell depletion and cryopreservation of umbilical cord blood (UCB)
39. Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes
40. Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years
41. Outcome of patients with acute myeloid leukemia who failed to respond to a single course of first-line induction therapy: a GIMEMA study of 218 unselected consecutive patients. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto
42. Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications
43. Diagnosis and classification of the acute leukemias: recent advances and controversial issues
44. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups.
45. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study.
46. New thrombopoietin receptor agonists for platelet disorders
47. Avatrombopag maleate
48. All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia
49. Lineage identification of acute leukemias: relevance of immunologic and ultrastructural techniques
50. RECOMBINANT INTERFERON ALPHA-2A, THYMOPENTIN AND LOW-DOSES OF CYTOSINE-ARABINOSIDE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES - A PILOT-STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.